CD8A and cancer: Th17 cells drive antitumor immune responses by recruiting immune cells into tumors, activating effector CD8(+) T cells, or even directly by converting toward the Th1 phenotype and producing IFN-γ, which mediates cancer regression in immunotherapy, including adoptive transfer and checkpoint blockade therapy [38].